Fexinidazole versus NECT for stage 2 Trypanosoma brucei gambiense human African trypanosomiasis: a multicentre, randomised, phase III trial
The Lancet Infectious Diseases — Vol. 26 — N° 4 — pp. 412-423
Résumé
This multicentre randomised phase III trial demonstrates non-inferiority of oral fexinidazole compared to the standard NECT regimen for stage 2 HAT, with a cure rate of 95.2% vs 93.8% at 18 months.
Auteurs et affiliations
Référence bibliographique
DOI
10.1016/S1473-3099(26)00045-2
PMID
Référence
The Lancet Infectious Diseases
Date de publication
2026-01-10